MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock
$2,428K
Proceeds from issuance of
warrants
$1,699K
Acquisitions of property and
equipment
-$83K
Proceeds from issuance of
pre-funded warrants
$609K
Net cash provided by
financing activities
$2,763K
Net cash used in
investing activities
$83K
Canceled cashflow
$1,973K
Net increase
(decrease) in cash and cash...
-$1,315K
Canceled cashflow
$2,846K
Accrued expenses
$442K
Depreciation and
amortization
$384K
Other liabilities
$358K
Accounts payable
$340K
Prepaid expenses and
other current assets
-$130K
Paid-in-kind interest
expense on promissory...
$100K
Stock-based compensation
expense
$55K
Contract liability
$53K
Proceeds from exercise of
warrants
-$833K
something is missing
-$609K
Proceeds from issuance of
debt
-$417K
Reduction of debt
liability
$97K
Reduction of finance lease
liability
$17K
Net cash used in
operating activities
-$4,161K
Canceled cashflow
$1,862K
Net loss
-$5,399K
Accounts receivable
$501K
Deposits
$16K
Operating lease
liabilities, net
-$7K
Back
Back
Cash Flow
source: myfinsight.com
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS)